share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  09/10 18:04

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of September 9, 2024, at 5:00 P.M. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that ZyVersa Therapeutics has met all the necessary regulatory requirements to proceed with the issuance of securities, which could include stocks, bonds, or other types of financial instruments. The SEC's notice of effectiveness is a standard procedure that signifies the company can now move forward with its plans to raise capital through the securities market.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of September 9, 2024, at 5:00 P.M. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that ZyVersa Therapeutics has met all the necessary regulatory requirements to proceed with the issuance of securities, which could include stocks, bonds, or other types of financial instruments. The SEC's notice of effectiveness is a standard procedure that signifies the company can now move forward with its plans to raise capital through the securities market.
ZyVersa Therapeutics, Inc.(一家生物制药公司)与美国证券交易委员会(SEC)达成了重要的里程碑,SEC宣布其S-3表格在2024年9月9日下午5:00生效。该表格是一份注册声明,允许公司向公众发行各种证券。该表格的生效意味着ZyVersa Therapeutics已满足所有必要的监管要求,可以继续发行证券,包括股票、债券或其他类型的金融工具。SEC的生效通知是一项标准程序,意味着公司现在可以继续通过证券市场筹集资金。
ZyVersa Therapeutics, Inc.(一家生物制药公司)与美国证券交易委员会(SEC)达成了重要的里程碑,SEC宣布其S-3表格在2024年9月9日下午5:00生效。该表格是一份注册声明,允许公司向公众发行各种证券。该表格的生效意味着ZyVersa Therapeutics已满足所有必要的监管要求,可以继续发行证券,包括股票、债券或其他类型的金融工具。SEC的生效通知是一项标准程序,意味着公司现在可以继续通过证券市场筹集资金。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息